Ignite Creation Date:
2024-05-06 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 2:15 PM
Study NCT ID:
NCT05073133
Status:
COMPLETED
Last Update Posted:
2024-05-31
First Post:
2021-09-20
Brief Title:
Safety and Efficacy of Intravenous OAV101 AVXS-101 in Pediatric Patients With Spinal Muscular Atrophy SMA OFELIA
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Muscular Atrophy Spinal |
Keywords:
| Name | View |
|---|---|
| loss of muscle strength | View |
| Zolgensma | View |
| OAV101 | View |
| AVXS 101 | View |
| gene therapy | View |
| Muscle atrophy | View |
| SBMA | View |
| spinal and bulbar muscular atrophy | View |
| spinal muscular atrophy | View |
| bulbar muscular atrophy | View |
| muscle function | View |
| myopathy | View |
| muscle wasting | View |
| atrophied muscle | View |